share_log

ALLARITY THERAPEUTICS INC | 8-K: Current report

SEC announcement ·  Mar 4 16:13
Summary by Moomoo AI
Allarity Therapeutics, Inc., a biopharmaceutical company, has reported the termination of employment of its Chief Medical Officer, Marie Foegh, M.D., as disclosed in a Form 8-K filing with the United States Securities and Exchange Commission. The termination was effective as of February 29, 2024. The company, listed on the Nasdaq Stock Market under the trading symbol ALLR, is classified as an emerging growth company. The report was officially signed by an authorized representative of Allarity Therapeutics, Inc. on March 4, 2024.
Allarity Therapeutics, Inc., a biopharmaceutical company, has reported the termination of employment of its Chief Medical Officer, Marie Foegh, M.D., as disclosed in a Form 8-K filing with the United States Securities and Exchange Commission. The termination was effective as of February 29, 2024. The company, listed on the Nasdaq Stock Market under the trading symbol ALLR, is classified as an emerging growth company. The report was officially signed by an authorized representative of Allarity Therapeutics, Inc. on March 4, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more